Top

Published in:

10-06-2022 | Migraine | Review Article

The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine

Authors: Simona Guerzoni, Carlo Baraldi, Luca Pani

Published in: Neurological Sciences | Issue 9/2022

Abstract

Chronic migraine (CM) is a great challenge for physicians dealing with headaches. Despite the introduction of the monoclonal antibodies (mAbs) acting against the calcitonin gene-related peptide (CGRP) that has revolutionized the treatment of CM, some patients still experience an incomplete relief. So, the association of two preventive treatments may be a reliable option for these patients. So, onabotulinumtoxinA (BT-A) and anti-CGRP mAbs may be used together, and some pre-clinical and clinical evidence of an additive action of the 2 drugs is emerging. In particular, since BT-A acts mainly on C-fibers and anti-CGRP mAbs on Aδ ones, their association may prevent the wearing-off phenomenon of BT-A, thus giving an additional benefit in those patients experiencing an incomplete response to BT-A alone. Despite this, the clinical studies available in the literature have a small sample size, often a retrospective design, and are heterogeneous in terms of the outcomes chosen. Considering this, the evidence of a favorable effect of the association between BT-A and anti-CGRP mAbs is still scarce. Furthermore, this association is explicitly forbidden by many National regulatory agencies, due to the high costs of both treatments. Anyway, their association could help in reducing the burden associated with the most severe cases of CM, thus relieving the direct and indirect costs of this condition. More well-designed studies with big samples are needed to unveil the real therapeutic gain of this association. Moreover, pharmacoeconomics studies should be performed, to assess the economic suitability of this association.

Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1–211. https://doi.org/10.1177/0333102417738202

Burch RC, Buse DC, Lipton RB (2019) Migraine: epidemiology, burden, and comorbidity. Neurol Clin 37:631–649. https://doi.org/10.1016/j.ncl.2019.06.001CrossRefPubMed

Safiri S, Pourfathi H, Eagan A, Mansournia MA, Khodayari MT, Sullman MJM, Kaufman J, Collins G, Dai H, Bragazzi NL, Kolahi AA (2022) Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain 163:e293-2309. https://doi.org/10.1097/j.pain.0000000000002275CrossRefPubMed

Agostoni EC, Barbanti P, Calabresi P, Colombo B, Cortelli P, Frediani F, Geppetti P, Grazzi L, Leone M, Martelletti P, Pini LA, Prudenzano MP, Sarchielli P, Tedeschi G, Russo A, the Italian chronic migraine group (2019) Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain 20:92. https://doi.org/10.1186/s10194-019-1038-4CrossRefPubMedPubMedCentral

Sacco S, Russo A, Geppetti P, Grazzi L, Negro A, Tassorelli C, Tedeschi G, Martelletti P (2020) What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group. Expert Rev Neurother 20:1275–1286. https://doi.org/10.1080/14737175.2020.1825077CrossRefPubMed

Rothrock JF, Adams AM, Lipton RB, Silberstein SD, Jo E, Zhao X, Blumenfeld AM, FORWARD Study investigative group (2019) FORWARD study: evaluating the comparative effectiveness of OnabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine. Headache 59:1700–1713. https://doi.org/10.1111/head.13653CrossRefPubMedPubMedCentral

Drellia K, Kokoti L, Deligianni C, Papadopoulos D, Mitsikostas DD (2021) Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. Cephalalgia 41:851–864. https://doi.org/10.1177/0333102421989601CrossRefPubMed

Sacco S, Braschinky M, Ducros A, Lampl C, Little P, Maassen van den Brink A, Pozo-Rosich P, Reuter U, Ruiz de la Torre E, Sanchez del Rio M, Sinclair AJ, Katsarava Z, Martelletti P (2020) European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine and Headache Alliance (EMHA). J Headache Pain. 21:76. https://doi.org/10.1186/s10194-020-01130-5CrossRefPubMedPubMedCentral

Torres-Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (2021) The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol 268:3789–3798. https://doi.org/10.1007/s00415-021-10523-8CrossRefPubMed

10.

D’Amico D (2012) Controversies in migraine: monotherapy. Neurol Sci 33:141–145. https://doi.org/10.1007/s10072-012-1059-0CrossRef

11.

Bramer WM, Rethlefsen ML, Kleijnen J, Franco OH (2017) Optimal database combination for literature searches in systematic review: a prospective exploratory study. Syst Rev 6:245. https://doi.org/10.1186/s13643-017-0644-yCrossRefPubMedPubMedCentral

12.

Edvinsson JCA, Viganò A, Alekseeva A, Alieva E, Arruda R, De Luca C, D’Ettore N, Frattale I, Kurnukhina M, Macerola N, Malenkova E, Maiorova M, Nivokova A, Rehulka P, Rapaccini V, Rosh,china O, Vanderschueren G, Zvaune L, Andreou AP, Haanes KA (2020) European Headache Federation School of Advanced Studies (EHF-SAS). The fifth cranial nerve in headaches. 21:65. 13.https://doi.org/10.1186/s10194-020-01134-1

13.

Noseda R, Melo-Carrillo A, Rony-Reuven N, Strassman AM, Burstein R (2019) Non-trigeminal nociceptive innervation of the posterior dura: implications to occipital headache. J Neurosci 39(1867–1880):14. https://doi.org/10.1523/JNEUROSCI.2153-18.2018CrossRef

14.

Levy D, Labastida-Ramirez A, MaassenVanDenBrink A (2019) Current understanding of meningeal and cerebral vascular function underlying migraine headache. Cephalalgia 39:1606–1622. https://doi.org/10.1177/033102418771350CrossRefPubMed

15.

Burstein R, Blake P, Schain A, Perry C (2017) Extracranial origin of headache. Curr Opin Neurol 30:263–271CrossRef

16.

Busch V, Jakob W, Juergens T, Schulte-Mattler W, Kaube H, May A (2006) Functional connectivity between trigeminal and occipital nerves revealed by occipital nerve blockade and nociceptive blink reflexes. Cephalalgia 26:50–55. https://doi.org/10.1111/j.1468-2982.2005.00992.xCrossRefPubMed

17.

Lennerz JK, Ruhle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, Messlinger K (2008) Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: difference between peripheral and central CGRP receptor distribution. J Comp Neurol 507:1277–1299. https://doi.org/10.1002/cne.21607CrossRefPubMed

18.

Iyengar S, Johnson KW, Ossipov MH, Aurora SK (2019) CGRP and the trigeminal system in migraine. Headache 59:659–681. https://doi.org/10.1111/head.13529CrossRefPubMedPubMedCentral

19.

Burstein R, Blumenfeld AM, Silberstein SD, Manack AA, Brin MF (2020) Mechanism of action on onabotulinumtoxinA in chronic migraine: a narrative review. Headache 60:1259–1272CrossRef

20.

Burstein R, Yamamura H, Malick A, Strassman AM (1998) Chemical stimulation of the intracranial dural induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 79:964–982CrossRef

21.

Burstein R, Cutrer MF, Yarnitsky D (2000) The development of cutaneous allodynia during a migraine attack: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 123:1703–1709CrossRef

22.

Blumenfeld A, Durham PL, Feoktistov A, Hay DL, Russo AF, Turner I (2021) Hypervigilance, allostatic load, and migraine prevention: antibodies to CGRP or receptor. Neurol Ther 10:469–497. https://doi.org/10.1007/s40120-021-00250-7CrossRefPubMedPubMedCentral

23.

Wattiez AS, Wang M, Russo AF (2019) CGRP in animal models of migraine. Handb Exp Pharmacol 255:85–107. https://doi.org/10.1007/164_2018_187CrossRefPubMedPubMedCentral

24.

Ashina H, Schytz HW, Ashina M (2018) CGRP in human models of primary headache. Cephalalgia 38:353–360. https://doi.org/10.1177/0333102416684344CrossRefPubMed

25.

Waskito A, Yamamoto Y, Raman S, Kano F, Yan H, Raju R, Afroz S, Morita T, Ikutame D, Okura K, Oshima M, Yamamoto A, Baba O, Matsuka Y (2021) Peripherally administered botulinum toxin type A localizes bilaterally in trigeminal ganglia of animal model. Toxin (Basel) 13:704. https://doi.org/10.3390/toxins13100704CrossRef

26.

Matak I, Riederer P, Lackovic Z (2012) Botulinum toxin’s axonal transport from periphery to the spinal cord. Neurochem Int 61:236–239. https://doi.org/10.1016/j.neuint.2012.05.001CrossRefPubMed

27.

Matak I, Back-Rojecky L, Filipovic B, Lackovic Z (2011) Behavioural and immunoistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 186:201–207. https://doi.org/10.1016/j.neuroscience.2011.04.026CrossRefPubMed

28.

Durham PL, Cady R, Cady R (2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44:35–42. https://doi.org/10.1111/j.1526-4610.2004.04007.xCrossRefPubMed

29.

Shimizu T, Shibata M, Toriumi H, Iwashita T, Funakubo M, Sato H, Kuroi T, Ebine T, Koizumi K, Suzuki N (2012) Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol Dis 48:367–378. https://doi.org/10.1016/j.nbd.2012.07.010CrossRefPubMed

30.

Zhang X, Strassman AM, Novack V, Brin MF, Burstein R (2016) Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors’ responses to stimulation of TRPV1 and TRPA1 channels: are we getting closer to solving this puzzle? Cephalalgia 36:875–886. https://doi.org/10.1177/0333102416636843CrossRefPubMedPubMedCentral

31.

Burstein R, Zhang XC, Levy D, Aoki RK, Brin MF (2014) Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia 34:853–869. https://doi.org/10.1177/0333102414527648CrossRefPubMedPubMedCentral

32.

Filipovic B, Matak I, Bach-Rojecky L, Lackovic Z (2012) Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy. PLoS One 7:e29803. https://doi.org/10.1371/journal.pone.0029803CrossRefPubMedPubMedCentral

33.

Lackovic Z, Filipovic B, Matak I, Helyes Z (2016) Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches. Br J Pharmacol 173:279–291. https://doi.org/10.1111/bph.13366CrossRefPubMed

34.

Melo-Carrilo A, Strassman AM, Schain AJ, Noseda R, Ashina S, Adams A, Brin MF, Burstein R (2019) Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats. Cephalalgia 39:1258–1365. https://doi.org/10.1177/0333102419873675CrossRef

35.

Noma N, Watanabe K, Sato Y, Imamura Y, Yamamamoto Y, Ito R, Maruno M, Shimizu K, Iwata K (2017) Botulinum neurotoxin type A alleviates mechanical hypersensitivity associated with infraorbital nerve constriction injury in rats. Neurosci Lett 637:96–101. https://doi.org/10.1016/j.neulet.2016.11.043CrossRefPubMed

36.

Matak I, Rossetto O, Lackovic Z (2014) Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons. Pain 155:1516–1526. https://doi.org/10.1016/j.pain.2014.04.027CrossRefPubMed

37.

Kitamura Y, Matsuka Y, Spigelman I, Ishihara Y, Yamamoto Y, Sonoyama W, Kamioka H, Yamashiro T, Kuboki T, Oguma K (2009) Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience 159:1422–1429. https://doi.org/10.1016/j.neuroscience.2009.01.066CrossRefPubMed

38.

Noseda R, Schain AJ, Melo-Carrillo A, Tien J, Stratton J, Mai F, Strassman AM, Burstein R (2020) Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier. Cephalalgia 40:229–240. https://doi.org/10.1177/0333102419896760CrossRefPubMed

39.

Melo-Carrillo A, Noseda R, Nir RR, Schain AJ, Stratton J, Strassman AM, Burstein R (2017) Selective inhibition of trigeminovascular neurons by fremanezumab: a humanized monoclonal anti-CGRP antibody. J Neurosci 37:7149–7163. https://doi.org/10.1523/JNEUROSCI.0576-17.2017CrossRefPubMedPubMedCentral

40.

Melo-Carrillo A, Strassman AM, Nir RR, Schain AJ, Noseda R, Stratton J, Burstein R (2017) Fremanezumab-a humanized monoclonal anti-CGRP antibody-inhibits thinly myelinated (Aδ) but not unmyelinated (C9 meningeal nociceptors. J Neurosci 37:10587–10596. https://doi.org/10.1523/JNEUROSCI.2211-17.2017CrossRefPubMedPubMedCentral

41.

Ohlsson L, Kronvall E, Stratton J, Edvinsson L (2018) Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries. J Headache Pain 19:66. https://doi.org/10.1186/s10194-018-0905-8CrossRefPubMedPubMedCentral

42.

Grell AS, Hanes KA, Johansson SE, Edvinsson L, Sams A (2019) Fremanezumab inhibits vasodilatatory effects of CGRP and capsaicin in rat cerebral artery-potential role in conditions of severe vasoconstriction-. Eur J Pharmacol 864:172726. https://doi.org/10.1016/j.ejphar.2019.172726CrossRefPubMed

43.

Zeller J, Poulsen KT, Sutton JE, Abdiche YN, Collier S, Chopra R, Garcia CA, Pons J, Rosenthal A, Shelton DL (2008) CGRP function-blocking antibodies inhibit neurogenic vasodilation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol 155:1093–1103. https://doi.org/10.1038/bjp.2008.334CrossRefPubMedPubMedCentral

44.

Schain AJ, Melo-Carrillo A, Stratton J, Strassman AM, Burstein R (2019) CSD-induced arterial dilatation and plasma protein extravasation are unaffected by fremanezumab. implication for CGRP’s role in migraine with aura. J Neurosci 39:6001–6011. https://doi.org/10.1523/JNEUROSCI.0232-19.2019CrossRefPubMedPubMedCentral

45.

Christensen SL, Petersen S, Kristensen DM, Olesen J (2019) Munro G- Targeting CGRP via receptor antagonism and antibody neutralization in two distinct rodent models of migraine-like pain. Cephalalgia 39:1827–1837. https://doi.org/10.1177/0333102419861726CrossRefPubMed

46.

Toni T, Tamanaha R, Newman B, Liang Y, Lee J, Carrazana E, Vajjala V, Viereck J, Liow KK (2021) Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series. Neurol Sci 42:5373–5376. https://doi.org/10.1007/s10072-021-05547-xCrossRefPubMed

47.

Cohen F, Armand C, Lipton RB, Vollbracht S (2021) Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as add-on therapy to onabotulinumtoxinA in patients with chronic migraine. Pain Med 22:1857–1863. https://doi.org/10.1093/pm/pnab093CrossRefPubMed

48.

Mechtler L, Saikali N, McVige J, Hughes O, Traut A, Adams AM (2022) Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to onabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine. Front Neurol 12:788159. https://doi.org/10.3389/fneur.2021.788159CrossRefPubMedPubMedCentral

49.

Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A (2021) Additive interaction between onabotulinumtoxin-A and erenumab in patients with refractory migraine. Front Neurol 12:656294. https://doi.org/10.3389/fneur.2021.656294CrossRefPubMedPubMedCentral

50.

Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, Adams AM (2021) Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antidoby therapy added to onabotulinumtoxinA: a retrospective chart review. Pain Ther 10:809–826. https://doi.org/10.1007/s40122-021-00264-xCrossRefPubMedPubMedCentral

51.

Armanious M, Khalil N, Lu Y, Jimenez-Sanders R (2020) Erenumab and onabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis. J Pain Palliat Care Pharmacother 35:1–6. https://doi.org/10.1080/15360288.2020.1829249CrossRefPubMed

52.

Boudreau GP (2020) Treatment of chronic migraine with erenumab alone or as an add on therapy: a realworld observational study. Anesth Pain Res 4(1–4):25

53.

Ozudogru SN, Bartell JW, Yuan H, Digre KB, Baggaley SK (2020) The effect of adding calcitonin gene-related peptide monoclonal antibodies to onabotulinum toxin A therapy on headache burden: a retrospective observational case series. Headache 60:1442–1443CrossRef

54.

Lu J, Zhang Q, Guo X, Liu W, Xu C, Hu X, Ni J, Lu H, Zhao H (2021) Calcitonin gene-related peptide monoclonal antibody versus botulinum toxin for the preventive treatment of chronic migraine: evidence from indirect treatment comparison. Front Pharmacol 12:631204. https://doi.org/10.3389/fphar.2021.631204CrossRefPubMedPubMedCentral

55.

Pellesi L, Do TP, Ashina H, Ashina M, Burstein R (2020) Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: is there a rationale? Headache 60:1056–1065. https://doi.org/10.1111/head.13843CrossRefPubMed

56.

Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L (2013) Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain 14:1289–1303. https://doi.org/10.1016/j.jpain.2013.03.010CrossRefPubMed

57.

Edvinsson JCA, Warfringe K, Krause DN, Blixt FW, Sheykhzade M, Edvinsson L, Haanes KA (2019) C-fibers may modulate adjacent Adelta-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system. J Headache Pain 20:65. https://doi.org/10.1186/s10194-019-1055-3CrossRef

58.

Eftekhari S, Edvinsson L (2011) Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level. BMC Neurosci 12:112. https://doi.org/10.1186/1471-2202-12-112CrossRefPubMedPubMedCentral

59.

Masters-Israilov A, Robbins MA (2019) OnabotulinumtoxinA wear-off phenomenon in the treatment of chronic migraine. Headache 59:1753–1761. https://doi.org/10.1111/head.13638CrossRefPubMed

60.

Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35:478–488. https://doi.org/10.1177/0333102414547138CrossRefPubMed

61.

Orlando V, Mucherino S, Monetti VM, Trama U, Menditto E (2020) Treatment patterns and medication adherence among newly diagnosed patients with migraine: a drug utilisation study. BMJ Open 10:e038972. https://doi.org/10.1136/bmjopen-2020-038972CrossRefPubMedPubMedCentral

62.

Guerzoni S, Pellesi L, Baraldi C, Cainazzo MM, Negro A, Martelletti P, Pini LA (2017) Long-term treatment benefits and prolonged efficacy of onabotulinumtoxinA in patients affected by chronic migraine and medication overuse headache over 3 years of therapy. Front Neurol 8:586. https://doi.org/10.3389/fneur.2017:00586CrossRefPubMedPubMedCentral

63.

Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Long-term effectiveness of three anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score. CNS Drugs 36:191–202CrossRef

Title: The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine
Authors: Simona Guerzoni
Carlo Baraldi
Luca Pani
Publication date: 10-06-2022
Publisher: Springer International Publishing
Keywords: Migraine
Medication Overuse Headache
Headache
Erenumab
Fremanezumab
Published in: Neurological Sciences / Issue 9/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-022-06195-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2022

FDG PET in the differential diagnosis of degenerative parkinsonian disorders: usefulness of voxel-based analysis in clinical practice

Greater occipital nerve blockade in cluster headache: effectiveness and safety of a combined injection protocol

Sex and gender differences in migraines: a narrative review

Mindfulness and other behavioral approaches

Sport and migraine—a dynamic relationship

Predictive value of quantitative pupillometry in patients with normal pressure hydrocephalus undergoing temporary CSF diversion